Alphapointe received notice from the United States Patent and Trademark Office that the organization’s application for a patent for the Junctional Hemorrhage Control Plate has been formally approved.
The patent approval is the latest in a series of developments for Alphapointe’s Tactical/Medical Division, which now has eight patents/patent-pending products designed to improve the well-being and safety of people around the world.
“This patent is yet another step forward for Alphapointe to become one of our nation’s leading tactical/medical device manufacturers,” said Alphapointe President and CEO Reinhard Mabry. “The Junctional Hemorrhage Control Plate is a unique device unlike anything else currently available. It’s a critical development because it fills a void for our military personnel that will save lives.”
The Junctional Hemorrhage Control Plate (JHCP) works in tandem with another Alphapointe patented medical device, the Tactical Mechanical Tourniquet (TMT), to stop blood loss in areas where tourniquets can’t be applied, such as the groin. Currently, there are existing available products to address this issue, but they are not lightweight and are traditionally only carried by medical personnel. Like the TMT, the JHCP is highly portable and designed to be carried and used by anyone with a minimal amount of training, particularly in military and first responder settings.
The JHCP is available to U.S. military branches as well as to law enforcement organizations, first responders and the general public. The JHCP is also available through Alphapointe’s distribution partner, Safeguard Medical, under the product name “TQ-RAM.”
Like other Alphapointe tactical/medical devices, the JHCP was tested in collaboration with military personnel at Ft. Hood in Texas, Schofield Barracks in Hawai’i and with Wake Forest University’s Operational Medicine Division, which provides advanced medical training to elite medics and special forces from the U.S. armed services and other government agencies as well as allied military forces from around the globe.
The JHCP is the fourth tactical/medical product developed by Alphapointe in the past five years. Previously developed items – largely used by branches of the U.S. military – include the Tactical Mechanical Tourniquet (TMT), the Tactical Pneumatic Tourniquet (TPT) and the Rigid Immobilization System for Extremities (RISE) Splint. To date, Alphapointe has produced nearly 750,000 life-saving and tactical/medical devices, which has created sustainable jobs for more than 25 Americans, most of whom are people who are blind. In March, Alphapointe donated nearly 5,000 medical-related items to the Ukraine Relief Effort, including 2,500 TMTs.